Castle Biosciences

$33.94 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Castle Biosciences

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company has two market proprietary products, DecisionDx-Melanoma and DecisionDx-UM, and have two active proprietary products in development DecisionDx-UM and DecisionDx-Melanoma. The Company is developing a treatment plan for certain cancers using clinical and pathology factors. Its lead product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP), a test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer.

Stock Analysis

last close $33.94
1-mo return 31.4%
3-mo return 78.9%
avg daily vol. 231.62T
52-week high 78.59
52-week low 15.58
market cap. $893M
forward pe -
annual div. -
roe -10.6%
ltg forecast -
dividend yield -
annual rev. $110M
inst own. 82.7%
baraka

Subscribe now for daily local and international financial news

Subscribe